Novartis India Limited has scheduled its 78th Annual General Meeting (AGM) for Thursday, September 24, 2026. The meeting will commence at 11:00 am and be conducted through Video Conferencing or Other Audio-Visual Means.

The company disclosed this schedule in compliance with Ministry of Corporate Affairs and SEBI circulars. The Annual Report for FY26, containing the AGM notice, is available on the company website.

Voting Details

Remote e-voting will begin on Monday, September 21, 2026, at 9:00 am and conclude on Wednesday, September 23, 2026, at 5:00 pm. Shareholders holding shares as on the cut-off date of Thursday, September 17, 2026, are eligible to vote.

Members attending the AGM who did not cast their votes remotely may vote electronically during the meeting. This process adheres to Section 108 of the Companies Act, 2013, and Regulation 44 of the SEBI Listing Regulations.

Novartis announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib for relapsing multiple sclerosis on September 1, 2026. The oral Bruton’s tyrosine kinase (BTK) inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate and inflammatory brain lesions.

The trials met their primary endpoint, significantly reducing the annualized relapse rate compared to the active comparator. Remibrutinib also showed superiority on all key secondary endpoints within each trial, including a reduction in MRI lesions. These results establish remibrutinib as a BTK inhibitor achieving significant reductions in annualized relapse rate across two Phase III studies in adults with relapsing multiple sclerosis.

Clinical Efficacy and Safety

Remibrutinib delivered clinically meaningful reductions in key secondary endpoints related to disability progression. A preplanned combined analysis of REMODEL-1/-2 showed a positive trend in 3-month confirmed disability progression and nominal significance in 6-month confirmed disability progression.

The safety profile was consistent with the broader development program, which comprises more than 4,500 clinical trial participants across multiple indications. Remibrutinib was well tolerated with no liver safety signal, including no cases meeting Hy’s Law criteria.

What the Numbers Show

The clinical data indicates that remibrutinib addresses both inflammatory activity and disability progression simultaneously. While the primary endpoint focused on relapse rates, the secondary data points to potential long-term benefits in slowing disease advancement, supported by the nominal significance in 6-month confirmed disability progression.

Next Steps

Novartis plans to present late-breaking data at MSToronto2026 and intends to host an investor call following the congress presentation. The company plans to seek regulatory approval for remibrutinib in relapsing multiple sclerosis globally.

Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis, stated that an unmet need remains for oral therapies delivering robust relapse prevention while maintaining a favorable safety profile. He noted that the findings reinforce the company’s ambition to drive innovation in multiple sclerosis care.